Bendamustine HCL for Injection (box of 1 vial)
Bendamustine HCL for Injection (box of 1 vial)
*Packaging color may differ according to distribution region.

Bendamustine HCL for Injection

Bendamustine HCL for Injection is an antineoplastic medicine used for cancer chemotherapy. This anti-cancer drug is produced by AdvaCare Pharma in its ISO/GMP-certified facilities, where rigorous quality and safety inspections are conducted at every stage of production.



What is Bendamustine HCL?

Therapeutic Class:

Active Ingredients: Bendamustine HCL

Bendamustine HCL for Injection is an antineoplastic drug used in chemotherapy treatment for certain cancers of the blood. It is indicated for the treatment of chronic lymphocytic leukemia. It is also used to treat indolent non-Hodgkin's lymphoma that has been unresponsive to other treatments.

Bendamustine Hydrochloride is classified as an alkylating agent. It works by alkylating (adding an alkyl group) and cross-linking DNA, which causes DNA fragmentation, inhibition of protein synthesis, and cell death.

AdvaCare is a GMP manufacturer of Bendamustine HCL for Injection. We distribute a wide range of high-quality and cost-effective oncology medications. These medications have been manufactured in our facilities in China, India, and the USA.

Why choose us as your Bendamustine HCL manufacturer?

AdvaCare Pharma manufactures a variety of oncology medications, including Bendamustine HCL for Injection, at GMP-certified facilities. We are committed to producing cost-effective, high-quality cancer treatments that meet the highest industry standards and are readily available to cancer patients worldwide. Our global reach extends to over 65 markets, where we supply our products to distributors, hospitals, pharmacies, NGOs, and government institutions.


What is Bendamustine HCL used for?

It is used to treat certain types of cancers, such as:

How should Bendamustine HCL Powder for Injection be used?

This medication has been manufactured as a powder, which is stored in a vial. The powder is to be prepared into a solution, and after reconstitution, it should be administered by slow injection into a vein.

As Bendamustine Hydrochloride for Injection is a cytotoxic drug, caution should be used when preparing and administering the solution. Goggles, gloves, and protective gowns are recommended.

What dosage should be used?

For chronic lymphocytic leukemia (CLL), the usual dose is 100mg/m² per dose, given on days 1 and 2 of a 28 day cycle. The cycle can be repeated up to 6 times.

For indolent B-cell non-Hodgkin lymphoma, the usual dose is 120mg/m² per dose, given on days 1 and 2 of a 28 day cycle. The cycle can be repeated up to 8 times.

The usual dose for an adult is 25mg. However, the exact dosage is dependent on the patient and treatment plan. Refer to a doctor or pharmacist for guidelines on dosage. Do not exceed what they advise.

Side Effects

As with all pharmaceuticals, some unwanted effects can occur from the use of Bendamustine HCL for Injection.

Common side effects include, but may not be limited to:

  • gastrointestinal effects (vomiting, diarrhea, upset stomach)
  • fever or cough
  • rash
  • headache
  • rash

Seek medical attention if the following develop:

  • fever or chills during or after treatment
  • signs of infection the injection site
  • severe gastrointestinal effects that do not subside
  • signs of a liver problem
  • signs of low blood cell count
  • signs of tumor cell breakdown

For a comprehensive list of all possible effects, consult a doctor.

If any symptom persists or gets worse, or you notice any other symptoms, please call your doctor immediately.


Do NOT use Bendamustine HCL for Injection if: • You are allergic to any component of the powder.

Consult with a doctor about any medications you are taking before treatment with Bendamustine HCL for Injection. This drug is known to interact with allopurinol, as well as other medications.

Do not take Bendamustine Hydrochloride during pregnancy, as it may cause birth defects. It is important for both women and men being treated with this drug to use an effective method of birth control. For women, continue birth control for at least 6 months after treatment, and at least 3 months after treatment for men. Inform a doctor as soon as possible if pregnancy occurs during treatment with Bendamustine HCL. Do not breastfeed for at least 1 week after treatment.

Bendamustine HCL may not be suitable for patients with certain conditions, including:

  • weakened immune function
  • current infection
  • tuberculosis
  • herpes zoster
  • electrolyte imbalance
  • liver or kidney disease
  • current smoker

Driving or operating machinery should be okay, as the medication should not cause any relevant symptoms.

*Regulatory compliance may vary according to production standard, import requirements and/or manufacturing origin.

You might be interested in...

Methotrexate Injection (box of 1 vial)
Methotrexate Injection
Letrozole Tablets (box of 100 tablets)
Letrozole Tablets
Tamoxifen Tablets (box of 100 tablets)
Tamoxifen Tablets
Granisetron HCL Injection (box of 1 vial)
Granisetron HCL Injection
Anastrozole Tablets (box of 100 tablets)
Anastrozole Tablets
Exemestane Tablets (box of 30 tablets)
Exemestane Tablets
Ondansetron HCL Tablets (box of 100 tablets)
Ondansetron Tablets
Hydroxyurea Capsules (box of 100 capsules)
Hydroxyurea Capsules

Why AdvaCare Pharma?

As an industry leader, we are aware of our responsibility to provide affordable and sustainable solutions to improve healthcare worldwide.

High Quality Affordable Products
Globally Recognized Brands
Wide Product Range
Regulatory Affairs Expertise
Flexible Production Lines
Marketing & Logistics Support